U.S. scientists recreate nerve disease to study it
By Julie Steenhuysen
CHICAGO (Reuters) - U.S. scientists have created the first human model for studying a devastating nerve disease, which allows them to watch how the disease develops and could help researchers find a way to treat it.
Using skin cells from a child with spinal muscular atrophy, a genetic disease that attacks motor neurons in the spinal cord, researchers grew batches of nerve cells with the same genetic defects. The finding allowed scientists to watch the nerve cells die off.
“Now we can start from the beginning of development and replay the disease process in the lab dish,” Clive Svendsen of the University of Wisconsin-Madison said in a telephone interview.
The finding, reported on Sunday in the journal Nature, marks the latest advance in research that reprograms ordinary cells to look and act like embryonic stem cells — the master cells of the body that can produce any type of tissue or blood cell.
Spinal muscular atrophy is the most common cause of childhood death caused by a genetic mutation, Svendsen said. It is caused by a deficiency of a protein called SMN, for survival of motor neurons.
“That SMN protein is important for motor neuron survival. They are the cells that make muscles move,” Svendsen said.
Infants with the most severe form the disease develop normally for the first six months of life, and then gradually develop muscle weakness and loss of motor control.
“They end up completely paralyzed,” Svendsen said, adding they typically die around age 2.
MAKING NEURONS
Svendsen’s team made motor neurons that contained the genetic defect that causes SMA with a powerful new type of cell called induced pluripotent stem cells, or iPS cells, which behave like embryonic stem cells.
The researchers used skin cells from a child with SMA to make iPS cells, and induced these cells to become motor neurons. Because every cell in the body contains the same genetic instructions, the motor neurons made from the child also carry the genetic disease.
The team also made motor neurons with cells from the child’s healthy mother.
After two months, the motor neurons from the child’s cells began to die, while the mother’s neurons kept developing normally.
“We suddenly had a split and it was related to the lack of the SMN protein,” Svendsen said.
Since iPS cells can grow for months or years in the lab, the experiment can be repeated in many batches of cells. Continued…
--------------------------------------------------------------------------------------------Related Posts:
LONDON (Reuters) - European regulators on Thursday ruled against allowing a patent on developing human embryonic stem cells, a decision that could stifle research by stem cell companies for commercial purposes. An appeal panel at the European Patent Office upheld a June decision to reject a patent application regarding the use of stem cells filed by
Full Post: European agency rules against stem cell patents
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - The U.S. Food and Drug Administration has cleared the way for the world’s first study of human embryonic stem cell therapy, Geron Corp said on Friday. The California biotechnology company plans to start a clinical trial to try to use the stem cells to regrow nerve tissue in patients with acute spinal cord
Full Post: FDA allows first test of human stem cell therapy
--------------------------------------------------------------------------------------------
By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Researchers trying to find ways to transform ordinary skin cells into powerful stem cells said on Sunday they found a shortcut by “sprinkling” a chemical onto the cells. Adding the chemical allowed the team at the Harvard Stem Cell Institute in Massachusetts to use just two genes
Full Post: Researchers find easier way to make stem cells
--------------------------------------------------------------------------------------------
By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Stem cell advocates and researchers are eagerly awaiting the moment next year when president-elect Barack Obama rescinds a directive that limits federal funding of human embryonic stem-cell research. The directive was one of President George W. Bush’s first major acts after taking office in 2001, and Obama
Full Post: Stem cell supporters await their Obama moment
--------------------------------------------------------------------------------------------
By Ben Hirschler LONDON (Reuters) - Danish drugmaker Novo Nordisk A/S is turning to stem cells in the hunt for a cure for diabetes. The world leader in diabetes care said on Thursday it had launched a new collaboration to develop a treatment for type 1 diabetes by programing stem cells to turn into insulin-producing cells. The alliance
Full Post: Novo taps stem cells in hunt for diabetes cure